Dataset Information


Multilineage dysplasia does not influence prognosis in patients with CEBPA mutated AML supporting the WHO proposal to classify these patients as a unique entity

ABSTRACT: By WHO 2008, CEBPA-mutated AML became a provisional subentity, but it remains to be clarified how CEBPAmut AML with multilineage dysplasia (MLD; ≥50% dysplastic cells in 2-3 lineages) but no other MDS-related feature should be classified. We investigated 108 CEBPAmut AML (15.7-87.6 years) for the impact of MLD and genetic features. MLD-positive patients differed from MLD-negative only by lower mean WBC counts (p=0.004), but not by other blood values, biologic characteristics, cytogenetic risk profiles, or additional molecular markers (NPM1mut, FLT3-ITD/TKD, RUNX1, MLL-PTD, IDH1/2). Biallelic CEBPAmut differed from wild-type-cases by differential expression of 213 genes, but did not differ significantly between MLD-positive/-negative patients. Survival outcomes were improved for females and those <60 years, intermediate versus adverse karyotypes (p=0.021), and for biallelic versus monoallelic/homozygous CEBPAmut (p=0.060) in case of FLT3-ITD-negativity. In contrast, 2-year OS (MLD+: 56.5%; MLD-: 65.5%) and 2-year EFS (MLD+: 13.8 months; MLD-: 16.3 months) did not differ significantly between MLD-positive/-negative patients. By univariable Cox regression analysis, gender, age, WBC count and MRC-cytogenetic risk category only were prognostically relevant for OS, while MLD was irrelevant. Therefore, CEBPAmut AML patients should be characterized only according to mut-status, cytogenetic risk groups, or additional mutations, whereas dysplasia is not relevant for this subtype. The sample preparation assay for gene expression profiling using Affymetrix HG-U133 Plus 2.0 microarrays and subsequent data analysis were previously described. Only cases with biallelic CEBPA mutations were investigated by gene expression profiling due to previous reports that only double mutated cases conferred a specific gene expression signature, while monoallelic cases could not be discriminated from CEBPA wild-type cases. We performed comparison of gene expression profiles of 20 cases with biallelic CEBPA mutations and of 10 cases without CEBPA mutations.


ORGANISM(S): Homo sapiens  

SUBMITTER: Tamara Alpermann   Andreas Kowarsch  Vera Grossmann  Claudia Haferlach  Alexander Kohlmann  Susanne Schnittger  Ulrike Bacher  Torsten Haferlach  Wolfgang Kern  Katja Macijewski 

PROVIDER: E-GEOD-33223 | ArrayExpress | 2012-06-14



Dataset's files

Action DRS
E-GEOD-33223.README.txt Txt
E-GEOD-33223.eSet.r Other
E-GEOD-33223.idf.txt Idf Processed Raw
Items per page:
1 - 5 of 6
altmetric image


Multilineage dysplasia does not influence prognosis in CEBPA-mutated AML, supporting the WHO proposal to classify these patients as a unique entity.

Bacher Ulrike U   Schnittger Susanne S   Macijewski Katja K   Grossmann Vera V   Kohlmann Alexander A   Alpermann Tamara T   Kowarsch Andreas A   Nadarajah Niroshan N   Kern Wolfgang W   Haferlach Claudia C   Haferlach Torsten T  

Blood 20120322 20

In 2008, the World Health Organization introduced CEBPA (encoding the CCAAT/enhancer binding protein)-mutated acute myeloid leukemia (AML) as a provisional entity. However, the classification of CEBPA-mutated AML with multilineage dysplasia (MLD; ≥ 50% dysplastic cells in 2-3 lineages) remains to be clarified. In the present study, we investigated 108 CEBPA-mutated AML patients for the impact of MLD, karyotype, and additional mutations. MLD(+) patients differed from MLD(-) patients only by lower  ...[more]

Similar Datasets

1000-01-01 | S-EPMC2662648 | BioStudies
2020-01-01 | S-EPMC7643165 | BioStudies
2009-01-23 | E-GEOD-14468 | ArrayExpress
2009-01-21 | GSE14468 | GEO
2010-07-01 | GSE18018 | GEO
2012-12-01 | E-GEOD-34733 | BioStudies
2010-07-30 | E-GEOD-18018 | ArrayExpress
2014-01-01 | S-EPMC4230151 | BioStudies
1000-01-01 | S-EPMC2652095 | BioStudies
2014-01-01 | S-EPMC4172831 | BioStudies